Cerebral InfarctionCARPETNCT07041372
Cerebral Atherosclerosis Research With Positron Emission Tomography
An observational study of Cerebral Infarction, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are: Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among… Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Cerebral Infarction
- What is being tested?
- FDG-PET
- How many people
- 310 participants
- Where
- 1 siteSouth Korea
- Study dates
- 22 Jun 2021to 31 Aug 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged 19 years and older who were diagnosed and treated for acute cerebral infarction within 7 days and can voluntarily participate in the study.
Who may be able to join
- acute ischemic stroke patients who admitted within seven days after symptom onset
Who cannot join
- Patients with unstable vital signs or neurological symptoms
- Patients with estimated glomerular filtration rate less than 30ml/min
- Patients with uncontrolled diabetes requiring persistent insulin injection
- During pregnancy or while breastfeeding
- Patients with impaired consent capacity
- Patients with diagnosed/treatment for dementia
- Patients undergoing treatment for malignant tumors or serious autoimmune diseases
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Seoul National University Hospital
Seoul, Jong-ro Gu, 03080
About this study
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:
- Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
- Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.
Read more
Participants will:
- Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
- Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
- Maintain regular clinic visits for up to 24 months following the index stroke
- Conditions
- Cerebral Infarction
- Being tested
- FDG-PET
- Keywords
- cerebral infarction
- Medical subject headings
- Cerebral Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FDG-PETDiagnostic test
The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.
What is being measured
The primary outcome is the main question the study is designed to answer.
Vascular events
Stroke, myocardial infarction, vascular death
Measured: up to 24 months after index stroke
Secondary outcomes (1)
overall vascular events
primary vascular events plus transient ischemic attack, venous thromboembolism, peripheral artery disease requiring intervention or hospitalization
Measured: up to 24 months after index stroke
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2025
- Study start22 Jun 2021
- Primary completion28 Feb 2029 (estimated)
- Study completion31 Aug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral InfarctionStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 310 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jeong-Min Kim, Seoul National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07041372
- Sponsor's protocol ID
- CARPET
- Acronym
- CARPET
- Status last verified
- Jun 2025
- First submitted
- 19 Jun 2025
- Last updated
- 27 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cerebral Atherosclerosis Research With Positron Emission Tomography
- ClinicalTrials.gov ID
- NCT07041372
- Acronym / sponsor ID
- CARPET / CARPET
- Conditions
- Cerebral Infarction
- Keywords
- cerebral infarction
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 310 participants (estimated)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Study start
- 22 Jun 2021 (actual)
- Primary completion
- 28 Feb 2029 (estimated)
- Study completion
- 31 Aug 2029 (estimated)
- First posted
- 27 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:
- Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?
- Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.
Participants will:
- Undergo whole-body FDG PET once their neurological status has stabilized after stroke.
- Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.
- Maintain regular clinic visits for up to 24 months following the index stroke
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged 19 years and older who were diagnosed and treated for acute cerebral infarction within 7 days and can voluntarily participate in the study.
Key inclusion criteria (1 listed)
- acute ischemic stroke patients who admitted within seven days after symptom onset
Key exclusion criteria (7 listed)
- Patients with unstable vital signs or neurological symptoms
- Patients with estimated glomerular filtration rate less than 30ml/min
- Patients with uncontrolled diabetes requiring persistent insulin injection
- During pregnancy or while breastfeeding
- Patients with impaired consent capacity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FDG-PETThe participants undergo whole-body FDG PET once their neurological status has stabilized after stroke. | Diagnostic test | – |
Primary outcome
Vascular events
Time frame: up to 24 months after index stroke
Stroke, myocardial infarction, vascular death
1 secondary outcome
overall vascular events
Time frame: up to 24 months after index stroke
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Cerebral Infarction
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebral Infarction, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vascular events (time frame: up to 24 months after index stroke). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025.